Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 7/20 | 0.33 |
| ▸ | MMP9 | P14780 | 6/20 | 0.33 |
| ▸ | MMP3 | P08254 | 3/20 | 0.33 |
| ▸ | MMP7 | P09237 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22852563 | 0.89 | ALDH1A1 (0.34) | ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL3843251 | 0.89 | ALDH1A1 (0.34) | ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL10131087 | 0.87 | MMP1 (0.35) | MMP1MMP9MMP3MMP7 | |
| SCHEMBL14671246 | 0.87 | MMP1 (0.35) | MMP1MMP9MMP3MMP7 | |
| SCHEMBL8359421 | 0.87 | — | — | |
| SCHEMBL4405242 | 0.81 | MMP1 (0.38) | MMP1MMP9MMP3ALDH1A1 | |
| SCHEMBL23058690 | 0.78 | STING1 (0.39) | ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL4404117 | 0.78 | TSHR (0.41) | MMP1MMP9MMP3MMP7 | |
| SCHEMBL31248259 | 0.78 | STING1 (0.39) | ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL23040247 | 0.78 | STING1 (0.39) | ALDH1A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133141-B2 | Cysteine and cystine bioisosteres to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150175559-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY (US) | 2015-06-25 | — | — | US | disclosed |
| US-8962692-B2 | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140155440-A1 | CYSTEINE AND CYSTINE BIOISOSTERES TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | MARQUETTE UNIVERSITY (US) | 2014-06-05 | — | — | US | disclosed |
| US-20120220596-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | UWM RESEARCH FOUNDATION, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-8173809-B2 | Cysteine and cystine prodrugs to treat schizophrenia and reduce drug cravings | MARQUETTE UNIVERSITY (US) | 2012-05-08 | — | — | US | disclosed |
| US-20120046232-A1 | COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046232-A1 | COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR | GRM6, GRM5, GRM7 | MMP1 3930/4885MMP9 3309/4885MMP3 2317/4885 |
| US-20140155440-A1 | CYSTEINE AND CYSTINE BIOISOSTERES TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | CTH, CBS, SLC7A11 | MMP1 4269/4885MMP9 4578/4885MMP3 4280/4885 |
| US-20120220596-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | CTH, SLC7A11, CBS | MMP1 3432/4885MMP9 3949/4885MMP3 3366/4885 |
| US-20150175559-A1 | CYSTEINE AND CYSTINE PRODRUGS TO TREAT SCHIZOPHRENIA AND REDUCE DRUG CRAVINGS | SLC7A11, CBS, CTH | MMP1 3821/4885MMP9 3990/4885MMP3 3768/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.